ExoDiscovery provides an exosome‑based liquid biopsy platform that isolates RNA biomarkers from a 20 µL plasma sample and detects variant allele frequencies as low as 0.001% with >97% sensitivity. The system delivers comprehensive mutation reports within 24 hours, enabling oncologists and clinical labs to screen for early‑stage cancer and monitor treatment response in real time.
Funding
Funding not disclosed
Founders
Product
Problem
Current liquid biopsy methods rely on circulating tumor DNA, which has a short half-life and limited sensitivity, often requiring large blood volumes and long processing times. This results in delayed or missed detection of early-stage cancers and hampers timely monitoring of treatment response.
Solution
ExoDiscovery offers an exosome‑based liquid biopsy platform that isolates RNA biomarkers protected within naturally occurring exosomes in blood. The technology provides up to 10,000‑fold greater sensitivity than conventional PCR or NGS, detecting variant allele frequencies as low as 0.001% from a 20 µL plasma sample. Results are delivered within 24 hours, eliminating the typical 7–14 day turnaround. Two applications—ExoDiscovery Detect for early screening and ExoDiscovery Monitor for longitudinal treatment tracking—enable clinicians to identify cancer earlier and adjust therapies based on real‑time molecular data.
Target Audience
Primary customers are oncologists, molecular pathologists, and clinical laboratories seeking rapid, ultra‑sensitive liquid biopsy tests for early cancer detection and treatment monitoring.
Features
- Proprietary exosome isolation and digital droplet detection that captures RNA without amplification, reducing assay complexity and error rates
- Sensitivity >97% across all cancer stages, with the ability to detect biomarkers at concentrations 10,000× lower than standard methods
- 24‑hour turnaround from sample receipt to comprehensive mutation report
- Minimal sample requirement (20 µL plasma) compared to 10–20 mL for conventional liquid biopsies
- Integrated analytical platform presenting variant allele frequencies, mutation panels, and clinical significance in an intuitive dashboard
- Scalable biomarker panels expanding from EGFR/KRAS to additional targets such as MET, BRAF, ROS1, and RET